Kiltearn Partners LLP Sells 11,600 Shares of Gilead Sciences, Inc. $GILD

Kiltearn Partners LLP trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 7.9% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 134,400 shares of the biopharmaceutical company’s stock after selling 11,600 shares during the quarter. Gilead Sciences makes up approximately 3.0% of Kiltearn Partners LLP’s holdings, making the stock its 12th largest position. Kiltearn Partners LLP’s holdings in Gilead Sciences were worth $14,901,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Quadrant Capital Group LLC boosted its holdings in shares of Gilead Sciences by 27.3% during the 2nd quarter. Quadrant Capital Group LLC now owns 34,417 shares of the biopharmaceutical company’s stock valued at $3,816,000 after buying an additional 7,384 shares in the last quarter. Vinva Investment Management Ltd boosted its holdings in Gilead Sciences by 11.1% in the 2nd quarter. Vinva Investment Management Ltd now owns 86,886 shares of the biopharmaceutical company’s stock worth $9,616,000 after buying an additional 8,713 shares during the period. Te Ahumairangi Investment Management Ltd raised its position in shares of Gilead Sciences by 19.3% during the second quarter. Te Ahumairangi Investment Management Ltd now owns 59,376 shares of the biopharmaceutical company’s stock valued at $6,583,000 after buying an additional 9,624 shares during the last quarter. Choreo LLC boosted its stake in Gilead Sciences by 1.1% during the second quarter. Choreo LLC now owns 47,852 shares of the biopharmaceutical company’s stock valued at $5,305,000 after buying an additional 498 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in shares of Gilead Sciences by 0.8% in the 2nd quarter. Russell Investments Group Ltd. now owns 1,260,487 shares of the biopharmaceutical company’s stock worth $139,728,000 after buying an additional 10,620 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Insider Activity

In other Gilead Sciences news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction dated Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total value of $1,193,900.00. Following the completion of the transaction, the chief executive officer directly owned 581,203 shares of the company’s stock, valued at approximately $69,389,826.17. The trade was a 1.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Monday, November 17th. The shares were sold at an average price of $125.23, for a total value of $313,075.00. Following the completion of the transaction, the chief financial officer owned 154,555 shares in the company, valued at $19,354,922.65. The trade was a 1.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 115,146 shares of company stock valued at $14,012,141 over the last three months. 0.27% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research firms recently commented on GILD. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $135.00 price target on shares of Gilead Sciences in a research note on Friday, October 31st. Sanford C. Bernstein restated an “outperform” rating on shares of Gilead Sciences in a report on Monday, November 3rd. Wall Street Zen upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 15th. BMO Capital Markets set a $135.00 price objective on Gilead Sciences in a report on Tuesday. Finally, Morgan Stanley upped their price target on shares of Gilead Sciences from $143.00 to $147.00 and gave the company an “overweight” rating in a research note on Friday, October 31st. Two analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $130.65.

Gilead Sciences Stock Performance

GILD opened at $127.51 on Thursday. The stock’s 50 day simple moving average is $119.36 and its 200-day simple moving average is $114.25. The stock has a market cap of $158.20 billion, a PE ratio of 25.40, a P/E/G ratio of 0.81 and a beta of 0.32. Gilead Sciences, Inc. has a 1 year low of $88.57 and a 1 year high of $128.70. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.42 billion. During the same quarter in the prior year, the business posted $2.02 earnings per share. The company’s quarterly revenue was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Sell-side analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently 48.99%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.